Reviva Pharmaceuticals, Inc., a drug discovery and development company, has announced positive results from REFRESH, a Phase II clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder. REFRESH is a randomized, double-blind, ...
[Published Individual.com - Apr 19 2013]